Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › HIV

HIV

101 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HIV

1198 trials tracked for HIV: 321 in phase 3 or 4 and 116 with published results. The most-cited published study has 6953 citations.

1,198Trials tracked
321Phase 3 & 4
0Recruiting
116With published results
Phase distribution
Phase 4 145 Phase 3 176 Phase 2 239 Phase 1 127 Other / NA 511
  1. Phase 3 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed · 6,953 cited
  2. Phase 3 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men Completed · 5,127 cited
  3. Phase 4 Strategic Timing of Antiretroviral Treatment Completed · 2,794 cited
  4. Phase 3 Botswana TDF/FTC Oral HIV Prophylaxis Trial Completed · 2,022 cited
  5. Phase 3 Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth Completed · 1,421 cited
  6. Phase 3 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection Completed · 467 cited
Show 44 more trials
  1. Phase 3 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Completed · 463 cited
  2. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) Completed · 379 cited
  3. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Completed · 378 cited
  4. Phase 3 Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) Completed · 369 cited
  5. Phase 4 Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana Completed · 357 cited
  6. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) Completed · 346 cited
  7. Phase 3 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) Completed · 346 cited
  8. Phase 3 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Completed · 304 cited
  9. Phase 3 Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Completed · 222 cited
  10. Phase 3 Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment Completed · 196 cited
  11. Phase 3 Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) Completed · 168 cited
  12. Phase 3 Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants Completed · 158 cited
  13. Phase 3 Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. Completed · 156 cited
  14. Phase 3 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Completed · 150 cited
  15. Phase 4 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed · 145 cited
  16. Phase 3 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed · 138 cited
  17. Phase 4 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy Completed · 128 cited
  18. Phase 4 Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women Completed · 122 cited
  19. Phase 3 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Completed · 118 cited
  20. Phase 3 ODYSSEY (PENTA 20) Completed · 118 cited
  21. Phase 3 A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed Completed · 114 cited
  22. Phase 4 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed · 111 cited
  23. Phase 4 Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Completed · 111 cited
  24. Phase 3 HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children Completed · 111 cited
  25. Phase 3 Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection Completed · 110 cited
  26. Phase 3 Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study Completed · 108 cited
  27. Phase 4 HIV Persistence and Viral Reservoirs Completed · 98 cited
  28. Phase 3 To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women Completed · 96 cited
  29. Phase 3 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Completed · 85 cited
  30. Phase 3 Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting Completed · 80 cited
  31. Phase 4 Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study) Completed · 77 cited
  32. Phase 4 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals Completed · 69 cited
  33. Phase 4 PrEP Implementation for Mothers in Antenatal Care Completed · 63 cited
  34. Phase 3 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men Completed · 63 cited
  35. Phase 3 Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults Completed · 62 cited
  36. Phase 3 Vitamin D Supplementation in HIV Youth Completed · 60 cited
  37. Phase 3 Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen Completed · 57 cited
  38. Phase 3 Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand Completed · 56 cited
  39. Phase 3 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed · 51 cited
  40. Phase 3 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa Completed · 50 cited
  41. Phase 4 Study of Truvada for HIV Pre Exposure Prophylaxis Using Daily Directly Observed Therapy to Look at Potential Interactions Between Truvada and Hormone Therapy Completed · 49 cited
  42. Phase 4 Genetics and HIV-1 Protease Inhibitors Completed · 49 cited
  43. Phase 4 DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence Completed · 48 cited
  44. Phase 4 Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Completed · 46 cited

Showing the 50 most-cited and recently-updated of 1,198 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Injectable lenacapavir receives clinical recommendation for HIV preexposure prophylaxis in US
Infectious Disease
Injectable lenacapavir receives clinical recommendation for HIV preexposure prophylaxis in US New HIV prevention shot gets official recommendation. What does that mean?
A clinical recommendation supports the use of injectable lenacapavir for HIV preexposure prophylaxis in the United States.
Health experts now officially recommend an injectable shot as a new option for people at risk to prevent getting HIV.
CDC Apr 4, 2026
Report estimates proportion of U.S. adults with HIV not adhering to medication due to cost
Allergy & Immunology
Report estimates proportion of U.S. adults with HIV not adhering to medication due to cost Report examines how often U.S. adults with HIV skip medications due to cost
An observational report from May 2016-June 2017 estimated the proportion of U.S.
Cost barriers stop many U.S. adults with HIV from taking their prescribed medications, threatening their health outcomes between 2016 and 20…
CDC Apr 4, 2026
Global TB remains leading infectious disease killer, especially deadly for persons with HIV
Allergy & Immunology
Global TB remains leading infectious disease killer, especially deadly for persons with HIV What's the world's deadliest single infectious disease? It's still tuberculosis
An epidemiological report on global tuberculosis trends indicates TB is the leading cause of death from a single infectious disease worldwid…
Tuberculosis remains the world's deadliest single infectious disease, claiming more lives than malaria or HIV/AIDS, especially for people li…
CDC Apr 4, 2026
HIV testing remained low at US physician offices, community health centers, and EDs from 2009-2017
Allergy & Immunology
HIV testing remained low at US physician offices, community health centers, and EDs from 2009-2017 HIV testing rates stayed low at U.S. doctor visits and emergency departments for nearly a decade
An observational report found HIV testing rates remained low during visits to US physician offices, community health centers, and emergency …
HIV testing rates stayed low at U.S. doctor visits and emergency departments for nearly a decade, showing a concerning pattern that needs at…
CDC Apr 4, 2026
Policy review finds moderate to high readiness for social protection in TB, HIV, and malaria programs across five African nations
Primary Care & Family Medicine Guideline
Policy review finds moderate to high readiness for social protection in TB, HIV, and malaria programs across five African nations Study finds moderate readiness to link health and social support in five African nations
A review of 111 national policy documents from Kenya, Malawi, Mozambique, Nigeria, and Zambia assessed readiness to integrate social protect…
Five African nations show moderate readiness to link health care with social support for TB, HIV, and malaria, but lack permanent systems to…
Frontiers Apr 3, 2026
CDC-Funded Direct-to-Consumer HIV Self-Test Program Delivered Approximately 440,000 Tests
Gastroenterology
CDC-Funded Direct-to-Consumer HIV Self-Test Program Delivered Approximately 440,000 Tests CDC program delivered about 440,000 HIV self-tests directly to U.S. residents
A CDC-funded program evaluation reported that approximately 440,000 HIV self-tests were delivered to U.S.
A CDC-funded program delivered about 440,000 HIV self-tests directly to U.S. residents to make home testing more accessible.
CDC Apr 3, 2026
Updated PHS guidelines recommend HIV, HBV, and HCV testing for pediatric transplant candidates under 12
Gastroenterology
Updated PHS guidelines recommend HIV, HBV, and HCV testing for pediatric transplant candidates under 12 U.S. updates guidelines for HIV and hepatitis testing in young transplant candidates
Updated U.S. Public Health Service guidelines recommend testing for HIV, Hepatitis B, and Hepatitis C in transplant candidates under age 12.
U.S. doctors now must test children under 12 for HIV and hepatitis before organ transplants to protect both the patient and the donated orga…
CDC Apr 3, 2026
Nurse-led peer-supported education improves CD4 count and adherence in Thai MSM with HIV
Infectious Disease RCT
Nurse-led peer-supported education improves CD4 count and adherence in Thai MSM with HIV Can group support help men with HIV manage their health better?
A randomized controlled trial of 64 Thai MSM with HIV found that a culturally adapted, nurse-delivered, peer-supported self-management educa…
A supportive group program helped Thai men with HIV improve immune health, stick to their medication, and feel better after just three month…
Apr 3, 2026
Observational study examines syndemic conditions and condomless anal intercourse in transgender women
Psychiatry
Observational study examines syndemic conditions and condomless anal intercourse in transgender women What makes safe sex harder for transgender women in U.S. cities?
An observational surveillance report examined the relationship between structural and psychosocial syndemic conditions and condomless anal i…
Housing instability and discrimination create tough barriers to safe sex for transgender women across seven U.S. cities.
CDC Apr 3, 2026
Surgical staging for penile cancer in Zambia finds 37.5% metastasis yield in palpable nodes
Urology Cohort
Surgical staging for penile cancer in Zambia finds 37.5% metastasis yield in palpable nodes Study in Zambia finds surgical lymph node staging for penile cancer has modest yield
A prospective cross-sectional cohort study of 40 patients with invasive penile squamous cell carcinoma in Zambia (87.5% HIV seropositive) fo…
In Zambia, many swollen groin nodes in penile cancer patients do not contain cancer, suggesting less invasive tests might avoid unnecessary …
Frontiers Apr 3, 2026
Tailored text messages plus motivational interviewing sustain MVPA in older adults with HIV
Psychiatry RCT
Tailored text messages plus motivational interviewing sustain MVPA in older adults with HIV Tailored text messages help people with HIV over 50 maintain physical activity
In an RCT of 118 people with HIV aged ≥50, adding tailored text messages to motivational interviewing helped sustain moderate-to-vigorous ph…
Tailored text messages helped older adults with HIV keep exercising for nearly 50 minutes daily while those receiving general messages saw a…
medRxiv Apr 3, 2026
Meta-analysis finds 15.4% pooled TTI prevalence in Cameroonian blood donors, higher risk in family donors
Gastroenterology Meta-analysis
Meta-analysis finds 15.4% pooled TTI prevalence in Cameroonian blood donors, higher risk in family donors How many blood donations in Cameroon carry dangerous infections?
A systematic review and meta-analysis of 36 studies involving approximately 105,000 blood donations in Cameroon found a pooled transfusion-t…
A new analysis of over 100,000 blood donations in Cameroon found that 15.4% carry dangerous infections like HIV, hepatitis, or syphilis, wit…
Apr 2, 2026

Questions about HIV

Why does HIV/AIDS continue to have a disproportionate impact on Black people in the US?

HIV/AIDS disproportionately affects Black people in the US due to systemic inequities including healthcare access barriers, stigma, criminalization, and underrepresentation in research and community engagement.

Full answer →
How can machine learning predict my CD4 and CD8 counts if I have HIV/AIDS?

Machine learning models can predict your CD4 and CD8 counts by analyzing patterns in your routine blood tests, organ function, and other clinical data over time, helping doctors personalize your HIV care.

Full answer →
Can bictegravir and lenacapavir suppress HIV-1 just as well as my complex current regimen?

Yes, a once-daily bictegravir-lenacapavir single-tablet regimen is non-inferior to complex regimens for maintaining HIV-1 suppression at 48 weeks, based on phase 3 trial data.

Full answer →
Did the number of new HIV infections among gay men change recently?

No, the number of new HIV infections among gay men in the US did not change overall from 2010 to 2019.

Full answer →
Can an agricultural program help food insecure women with HIV in Kenya?

Yes, an agricultural program called Shamba Maisha reduced food insecurity and improved psychosocial outcomes for food insecure women with HIV in Kenya, including those who became pregnant.

Full answer →
What is the viral non-suppression rate for people with HIV in Uganda on dolutegravir?

In Uganda, about 6.4% of people with HIV on dolutegravir have viral non-suppression (viral load ≥1,000 copies/mL), based on a large routine-care cohort.

Full answer →
See all 6 questions about HIV →